Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies

Michael Scott, Dominic Clarke, Yonatan Lipsitz, Harvey Brandwein, Julie Allickson, Dalia Alzebdeh, Sasha Aleksic, Crystal Kraft, Lexan Lhu, Kenneth Cornetta

Research output: Contribution to journalArticlepeer-review


A key hurdle to ensuring patient access to cell and gene therapies (CGTs) and continued growth of the industry is the management of raw materials. The combination of rapid growth, individual product and process complexity and limited industry-specific guidance or awareness presents non-obvious risk mitigation challenges for transitioning from development to clinical application. Understanding, assessing and mitigating the varied raw material risks for CGT products during product and clinical development are critical for ensuring smooth transitions into commercialization and for preventing interruption of product supply to patients. This article presents a risk-based approach driven by concerns for patient safety that can help focus and coordinate efforts to address the most critical risk factors. Highlighted are some of the highest risk materials common to the manufacture of many CGTs, including the primary starting material, culture media, reagents and single-use components. Using a hypothetical gene-edited cell therapy as an example, we describe the general manufacturing process and subsequently incorporate the described methodology to perform a sample risk assessment. The practical approach described herein is intended to assist CGT manufacturers and suppliers in actively assessing materials early in development to provide a basic starting point for mitigating risks experienced when translating CGT products for clinical and long-term commercial application.

Original languageEnglish (US)
Pages (from-to)669-676
Number of pages8
Issue number11
StatePublished - Nov 2020


  • cell and gene therapy
  • manufacturability
  • raw material
  • risk analysis
  • risk management
  • risk mitigation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation


Dive into the research topics of 'Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies'. Together they form a unique fingerprint.

Cite this